Search Results 761-770 of 18280 for alopecia

1. A Study to Evaluate Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for Multiple Myeloma with Minimal Residual Disease (MRD) to Direct Therapy Duration - Mayo Clinic

   All ASCT-related toxicities must have recovered to ≤ Grade 1 (except for alopecia, fatigue and amenorrhea) prior to first randomization. Mucositis and ...

2. A Study of STX-0712 in Patients with Advanced Hematologic Malignancies - Mayo Clinic

   ... alopecia, nausea, and fatigue); Clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association class 3 or 4 congestive ...

3. When Breast Cancer Travels to the Brain: Laser Therapy - Mayo Clinic

   Fuel groundbreaking medical research! ... Your donation powers the future of medicine and helps save lives. Give Today.

4. A Clinical Study To Investigate The Efficacy And Safety Of An Investigational Combination Therapy With BNT324 And BNT327 In Patients With Advanced Lung Cancer - Mayo Clinic

   Have unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline.

5. Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma - Mayo Clinic

   residual alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose ...

6. A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma - Mayo Clinic

   Skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment;; Conditions not expected to recur in the absence of an external ...

7. A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) - Mayo Clinic

   Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE V5.0, Grade ≤ 1 or ...

8. A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers - Mayo Clinic

   (Exceptions include stable toxicities as a result of previous therapy such as alopecia, well controlled electrolyte or endocrine abnormalities, peripheral ...

9. A Study Evaluating AMG 424 in Subjects With Multiple Myeloma - Mayo Clinic

   ... alopecia or toxicities from prior anticancer therapy that are considered irreversible (defined as having been present and stable for > 4 weeks) which may be ...

10. A Study to Evaluate TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Note: except Neuropathy Grade ≤ 2, any grade alopecia, or bone marrow parameters [any of Grade 1 or 2 permitted if directly related to bone marrow involvement] ...